Charissa Patricelli

MD, DABAM, CCFP

Investigator, BC Children's Hospital
Medical Director, Perinatal Addictions, BC Women's Hospital + Health Centre

Women who use substances in pregnancy are an under-studied group that face unique contexts and barriers to services and supports. Left untreated, severe substance use disorders in pregnancy can present significant harms both to mother and baby, including overdose and/or mortality. It is imperative that all women have access to treatments and services that are effective, safe, and acceptable. The goal of our research is to generate evidence to support treatments for pregnant women who use substances, that will allow women with substance use disorders to bond with, and parent their newborns.

Academic Affiliations

  • Clinical Associate Professor, , Department of Family Practice, Faculty of Medicine, University of British Columbia
  • Research Theme: Evidence to Innovation
  • Research Group(s): Clinical Practice, Outcomes and Innovation

Contact Information

Location

4500 Oak Street, Vancouver, British Columbia, Canada, V6H 3N1

Rapid transition from high-dose methadone to buprenorphine-naloxone and long-acting buprenorphine in a perinatal patient with opioid use disorder: A case report

Heroin Addiction and Related Clinical Problems

Kreim, S. and Gordon, S. and Carter, N. and Dreyer, M. and Ketch, J. and Patricelli, C.J.

DOI: 10.62401/2531-4122-2024-67

Perinatal injectable opioid agonist therapy (iOAT) treatment experience: A qualitative study

Heroin Addiction and Related Clinical Problems

Patricelli, C. and Liu, R. and Gordon, S. and Carter, N. and Stewart, K. and Gouin, I. and Paquette, V. and Bone, J. and Urbanoski, K.

DOI: 10.62401/2531-4122-2024-46

Neonatal Opioid Withdrawal Syndrome (NOWS) Monitoring Not Requiring NICU Admissions: Examining Rooming-in as Standard Care

Canadian Journal of Addiction

Patricelli, C.J. and Ricci, T.A. and Doerksen, J. and Ziabakhsh, S. and Everett, R. and Cattoni, E. and Hamilton, D. and Carter, N. and Wittmann, L. and Berkman, J. and Gordon, S. and Abrahams, R.

DOI: 10.1097/CXA.0000000000000199

Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series

Journal of Addiction Medicine

Patricelli, C.J. and Chai, J. and Gordon, S. and Gouin, I.J. and Carter, N. and Stewart, K. and Paquette, V. and Urbanoski, K. and Albert, A.

DOI: 10.1097/ADM.0000000000001152

Breastfeeding on Injectable Opioid Agonist Therapy: A Case Report

Journal of Addiction Medicine

Patricelli, C.J. and Gouin, I.J. and Gordon, S. and Carter, N. and Albert, A. and Paquette, V. and Stewart, K. and George, S. and Urbanoski, K.

DOI: 10.1097/ADM.0000000000001055

Injectable Opioid Agonist Therapy in a Perinatal Population

Injectable opioid agonist therapy (iOAT) is an evidence-based treatment option for severe opioid use disorder (OUD). It is the highest intensity treatment option currently available in Canada for those with severe OUD, and has been successfully introduced in specialized clinics as a way to stabilize those for whom oral opioid agonist treatments have not been effective. However, there is a gap in the literature concerning iOAT administration efficacy and outcomes in perinatal populations. The iOAT-APP study aims to gather critical practice-based evidence for the administration of iOAT in pregnancy.

Related News

Every day, our researchers work towards breakthroughs to transform the lives of kids in BC and around the world. Learn about our latest innovations and advancements in child health.

Our Research

At BC Children’s, we are making discoveries that save lives and transform health care for children in our province and around the world. Our research portfolio includes basic, clinical, population, and public health research.

EXPLORE OUR RESEARCH

Stay in the Know

Sign up for compelling stories about innovative science, the doctors and researchers who turn ideas into discoveries and treatments, and the kids and families whose lives are changed.

This field is for validation purposes and should be left unchanged.